Sanofi-Aventis SA (NYSE: SNY) has completed its $4 billion purchase of Merck & Co.'s half interest in their veterinary medicine business, Merial Ltd., according to Associated Press on Friday.
Wall Street Grand is a leading online financial publication. We are pleased to alert investors of stocks that are on the move.
Sign Up for our Free Stock Newsletter
The move was required by regulators before Merck (NYSE: MRK) can close its $41 billion purchase of Schering-Plough Corp. (NYSE: SGP), which also sells animal health products.
Merial, a joint venture founded in 1997, sells two widely used pet medicines, flea-and-tick blocker Frontline and chewable heartworm preventer Heartgard. It also sells Ivomec, which kills parasites in hogs and cattle, and other medicines and vaccines for livestock.
Sanofi-Aventis said the acquisition should boost its net income in the first year after the deal, which is the same strategy behind Merck's plan to buy Schering-Plough. With the pharmaceutical industry, the other huge merger pending is the $68 billion acquisition of Wyeth (NYSE: WYE) by Pfizer Inc. (NYSE: PFE).
Pfizer will get Wyeth's booming biotech and vaccine businesses, the Fort Dodge animal health business and a consumer health division with well-known products including Chap Stick, Advil and Anacin pain relievers, and Preparation H for hemorrhoids.
Similarly, Merck will acquire Schering's biotech division, a consumer products business with staples like the Dr. Scholl's and Coppertone lines, and one of the industry's strongest pipelines of experimental drugs in development.
Sanofi-Aventis retains an option to buy Schering-Plough's animal health business after the combination of Merck and Schering-Plough is completed, although any such deal would have to be approved by regulators here and in other countries.
Merial ranked third last year in global animal health sales, with a market share of nearly 14 percent and revenue of about $2.7 billion. Schering-Plough's Internet animal health business was just ahead of that, with almost $3 billion in revenue last year.
Sanofi's executive vice president for global operations, Hanspeter Speck, will oversee Merial as a subsidiary of Sanofi. Merial has about 5,700 employees and operates in more than 150 companies worldwide.
In New York trading Friday morning, Sanofi shares jumped 63 cents to 36.79, while Merck shares were up 29 cents at $32.30.
Sign up for Today for our free Wall Street Grand newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Wall Street Grand
Wall Street Grand is the best investor relations company on the web. From Research Reports to Stock Profiles, we give you everything you need to make the best investment decisions daily. Each of our Featured Investment Opportunities hold premium characteristics to succeed even our own expectations making us the best kept secret of Wall Street.
To feature a company on our web site please contact us at the email listed below.
Wall Street Grand's stock profiles are intended to be stock ideas, NOT recommendations. Please do your own research before investing. Please click here to read the full disclaimer.
